Therapeutic considerations for disease progression in multiple sclerosis: Evidence, experience, and future expectations

Elliot Frohman, Olaf Stuve, Eva Havrdova, John Corboy, Anat Achiron, Robert Zivadinov, Per Soelberg Sorensen, J. Theodore Phillips, Brian Weinshenker, Kathleen Hawker, Hans Peter Hartung, Lawrence Steinman, Scott Zamvil, Bruce A C Cree, Stephen Hauser, Howard Weiner, Michael K. Racke, Massimo Filippi

Research output: Contribution to journalReview articlepeer-review

37 Scopus citations


In the management of patients with multiple sclerosis (MS), providers are all faced with the highly formidable challenge of ascertaining whether, and to what degree, disease-modifying therapy is effective in the individual patient. While much has been learned in randomized, controlled clinical trials, we cannot simply extrapolate the outcomes of these initiatives and apply them to the care of a single patient. In the future, the application of pharmacogenetic techniques, proteomics, and microarray analysis will yield novel profiling information on individual patients that will substantially refine the specific therapeutic questions of relevance: (1) What is the best treatment for an individual patient? (2) Which patients require intensive therapeutic combination regimens to optimize control of the disease process? (3) What are the appropriate drug dosing targets for an individual patient? and (4) Which patients will be predisposed to the development of drug-related adverse events? Such data may provide a novel variable of drug responsiveness that will mandate its inclusion into the process of covariate analyses for clinical trials.

Original languageEnglish (US)
Pages (from-to)1519-1530
Number of pages12
JournalArchives of neurology
Issue number10
StatePublished - Oct 2005

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology


Dive into the research topics of 'Therapeutic considerations for disease progression in multiple sclerosis: Evidence, experience, and future expectations'. Together they form a unique fingerprint.

Cite this